{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T04:18:42Z","timestamp":1775189922244,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T00:00:00Z","timestamp":1619568000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T00:00:00Z","timestamp":1619568000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the commonest of the hereditary kidney diseases\u00a0and mostly ensues in utero with signs delayed until after several decades. This study assessed the demographic, diagnostic (clinical and biochemical features) and therapeutic patterns among ADPKD patients who attended the nephrology unit of Komfo Anokye Teaching Hospital (KATH) from 2007 to 2018.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This cross-sectional retrospective analysis of ADPKD patient records was conducted at the nephrology unit of KATH in October 2020. The records of 82 ADPKD was used for this study. Demographic, clinical, biochemical, ultrasonographic and therapeutic data\u00a0was obtained, organized and analyzed with Statistical Package for the Social Sciences (SPSS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>ADPKD was most prevalent in people within the ages of 31\u201340 years (25.6\u2009%), with a male (52.4\u2009%) preponderance. The most common clinical features presented were flank pain (30.5\u2009%) and bipedal swelling (18.3\u2009%). Hypertension (42.7\u2009%), urinary tract infections (UTIs) (19.5\u2009%), and anemia (13.4\u2009%) were the most common complications reported. Average level of HDL-c was higher in females (1.7) than\u00a0in males (1.2) (<jats:italic>p<\/jats:italic>\u2009=\u20090.001). Hematuria (34\u2009%) and proteinuria (66\u2009%) were among the biochemical derangements presented. About 81.7\u2009% had CKD at diagnosis with the majority in stages 1 (27.0\u2009%), 3(23.2\u2009%) and 5 (20.3\u2009%). Poor corticomedullary differentiation was observed in 90.2\u2009% of participants and increased echogenicity was observed in 89.0\u2009% of the participants. Estimated GFR (eGFR) correlated positively with echotexture (<jats:italic>r<\/jats:italic>\u2009=\u20090.320,<jats:italic>p<\/jats:italic>\u2009=\u20090.005) and negatively with CMD (<jats:italic>r<\/jats:italic>= -0.303,<jats:italic>p<\/jats:italic>\u2009=\u20090.008). About 95.1\u2009% of patients were on conservative therapy including: 73.2\u2009%, 52.4\u2009%, 22.0\u2009%, 13.4\u2009%, 8.5\u2009% on Irebesartan\/Lisinopril, Nifecard XL, Hydralazine, Methyldopa and Bisoprolol respectively for hypertension; 26.8 and 3.7\u2009% on Gliclazide and Metformin respectively for Type 2 diabetes mellitus; 25.6\u2009%, 24.4 and 18.3\u2009% on CaCO<jats:sub>3<\/jats:sub>, fersolate and folic acid respectively as nutrient supplements with 4.9\u2009% of participants on renal replacement therapy (RRT).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>ADPKD occurs in people aged\u2009\u2265\u200931 years with a higher male preponderance. Clinical features include flank and abdominal pain, bipedal swelling, headache, amongst others. Uremia, hematuria, proteinuria, decreased eGFR, were the common biochemical derangements reported with higher severity detected in men. The therapeutic interventions mostly involved conservative therapy to manage symptoms and other comorbid conditions and rarely renal replacement therapy (RRT).<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12882-021-02336-8","type":"journal-article","created":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T06:03:03Z","timestamp":1619589783000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Demographic, diagnostic and therapeutic characteristics of autosomal dominant polycystic kidney disease in Ghana"],"prefix":"10.1186","volume":"22","author":[{"given":"Perditer","family":"Okyere","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard K.D.","family":"Ephraim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isaac","family":"Okyere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Attakorah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorcas","family":"Serwaa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace","family":"Essuman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert","family":"Abaka-Yawson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prince","family":"Adoba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,28]]},"reference":[{"key":"2336_CR1","doi-asserted-by":"crossref","unstructured":"Hajji M, Barbouch S, Harzallah A, Hedri H, Kaaroud H. of Kidney Diseases and Transplantation Renal Data from the Arab World Clinical Study on Autosomal Dominant Polycystic Kidney Disease among North Tunisians. 2019;30:175\u201384.","DOI":"10.4103\/1319-2442.252908"},{"key":"2336_CR2","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2215\/CJN.05900519","volume":"15","author":"T Suwabe","year":"2020","unstructured":"Suwabe T, Shukoor S, Chamberlain AM, Killian JM, King BF, Edwards M, et al. Epidemiology of autosomal dominant polycystic kidney disease in Olmsted county. Clin J Am Soc Nephrol. 2020;15:69\u201379.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2336_CR3","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/j.ajhg.2016.05.004","volume":"98","author":"B Porath","year":"2016","unstructured":"Porath B, Gainullin VG, Cornec-Le Gall E, Dillinger EK, Heyer CM, Hopp K, et al. Mutations in GANAB, encoding the glucosidase II\u03b1 subunit, cause autosomal-dominant polycystic kidney and liver disease. Am J Hum Genet. 2016;98:1193\u2013207.","journal-title":"Am J Hum Genet."},{"key":"2336_CR4","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1080\/14737159.2017.1358088","volume":"17","author":"X Song","year":"2017","unstructured":"Song X, Haghighi A, Iliuta I-A, Pei Y. Molecular diagnosis of autosomal dominant polycystic kidney disease. Expert Rev Mol Diagn. 2017;17:885\u201395.","journal-title":"Expert Rev Mol Diagn"},{"key":"2336_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0190430","volume":"13","author":"A Solazzo","year":"2018","unstructured":"Solazzo A, Testa F, Giovanella S, Busutti M, Furci L, Carrera P, et al. The prevalence of autosomal dominant polycystic kidney disease (ADPKD): A meta-analysis of European literature and prevalence evaluation in the Italian province of Modena suggest that ADPKD is a rare and underdiagnosed condition. PLoS One. 2018;13:1\u201320.","journal-title":"PLoS One"},{"key":"2336_CR6","doi-asserted-by":"crossref","unstructured":"Magistroni R. Tolvaptan: Clinical Evidence for Slowing the Progression of Autosomal Dominant Polycystic Kidney Disease. 2017.","DOI":"10.5301\/GTND.2017.17029"},{"key":"2336_CR7","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2147\/IJNRD.S125942","volume":"11","author":"L Sans-Atxer","year":"2018","unstructured":"Sans-Atxer L, Joly D. Tolvaptan in the treatment of autosomal dominant polycystic kidney disease: patient selection and special considerations. Int J Nephrol Renovasc Dis. 2018;11:41.","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"2336_CR8","doi-asserted-by":"crossref","unstructured":"Okyere P, Okyere I, Ephraim RKD, Attakorah J, Osafo C, Arhin B, et al. Spectrum and Clinical Characteristics of Renal Diseases in Ghanaian Adults: A 13-Year Retrospective Study. Int J Nephrol. 2020;2020.","DOI":"10.1155\/2020\/8967258"},{"key":"2336_CR9","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1056\/NEJMcp0804458","volume":"359","author":"JJ Grantham","year":"2008","unstructured":"Grantham JJ. Autosomal dominant polycystic kidney disease. N Engl J Med. 2008;359:1477\u201385.","journal-title":"N Engl J Med"},{"key":"2336_CR10","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/S0140-6736(18)32782-X","volume":"393","author":"E Cornec-Le Gall","year":"2019","unstructured":"Cornec-Le Gall E, Alam A, Perrone RD. Autosomal dominant polycystic kidney disease. Lancet. 2019;393:919\u201335. doi:https:\/\/doi.org\/10.1016\/S0140-6736(18)32782-X.","journal-title":"Lancet"},{"key":"2336_CR11","unstructured":"Singh NP, Gupta AK, Kaur G, Khanna T. Chronic Kidney Disease of Unknown Origin \u2013 What do we. 2020; April."},{"key":"2336_CR12","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.amjhyper.2004.06.020","volume":"17","author":"CL Kelleher","year":"2004","unstructured":"Kelleher CL, McFann KK, Johnson AM, Schrier RW. Characteristics of hypertension in young adults with autosomal dominant polycystic kidney disease compared with the general U.S. population. Am J Hypertens. 2004;17:1029\u201334.","journal-title":"Am J Hypertens"},{"key":"2336_CR13","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1093\/ndt\/gfs551","volume":"28","author":"HPH Neumann","year":"2013","unstructured":"Neumann HPH, Jilg C, Bacher J, Nabulsi Z, Malinoc A, Hummel B, et al. Epidemiology of autosomal-dominant polycystic kidney disease: An in-depth clinical study for south-western Germany. Nephrol Dial Transplant. 2013;28:1472\u201387.","journal-title":"Nephrol Dial Transplant"},{"key":"2336_CR14","doi-asserted-by":"publisher","first-page":"100887","DOI":"10.1016\/j.disamonth.2019.100887","volume":"66","author":"GB Colbert","year":"2020","unstructured":"Colbert GB, Elrggal ME, Gaur L, Lerma E V. Update and review of adult polycystic kidney disease. Disease-a-Month. 2020;66:100887. doi:https:\/\/doi.org\/10.1016\/j.disamonth.2019.100887.","journal-title":"Disease-a-Month"},{"key":"2336_CR15","doi-asserted-by":"publisher","first-page":"671","DOI":"10.4314\/ahs.v18i3.25","volume":"18","author":"FA Arogundade","year":"2018","unstructured":"Arogundade FA, Akinbodewa AA, Sanusi AA, Okunola O, Hassan MO, Akinsola A. Clinical presentation and outcome of autosomal dominant polycystic kidney disease in Nigeria. Afr Health Sci. 2018;18:671\u201380.","journal-title":"Afr Health Sci"},{"key":"2336_CR16","first-page":"1172","volume":"21","author":"A Chijioke","year":"2010","unstructured":"Chijioke A, Aderibigbe A, Olarenwaju TO, Makusidi AM, Oguntoyinbo AE. Prevalence and pattern of cystic kidney diseases in Ilorin, Nigeria. Saudi J Kidney Dis Transplant. 2010;21:1172.","journal-title":"Saudi J Kidney Dis Transplant"},{"key":"2336_CR17","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1053\/j.ackd.2009.12.002","volume":"17","author":"Y Pei","year":"2010","unstructured":"Pei Y, Watnick T. Autosomal Dominant Polycystic Kidney Disease. Adv Chronic Kidney Dis. 2010;17:115\u20137.","journal-title":"Adv Chronic Kidney Dis"},{"key":"2336_CR18","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1056\/NEJMoa0907419","volume":"363","author":"AL Serra","year":"2010","unstructured":"Serra AL, Poster D, Kistler AD, Krauer F, Raina S, Young J, et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med. 2010;363:820\u20139.","journal-title":"N Engl J Med"},{"key":"2336_CR19","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.1365-2796.2010.02280.x","volume":"269","author":"M Evans","year":"2011","unstructured":"Evans M, Tettamanti G, Nyr\u00e9n O, Bellocco R, Fored CM, Elinder C. No survival benefit from early-start dialysis in a population\u2010based, inception cohort study of Swedish patients with chronic kidney disease. J Intern Med. 2011;269:289\u201398.","journal-title":"J Intern Med"},{"key":"2336_CR20","first-page":"bcr2013201637","volume":"2014","author":"SK Mandal","year":"2014","unstructured":"Mandal SK, Ganguly J, Mondal SS, Sil K. An unusual association of autosomal polycystic kidney disease and multiple myeloma. Case Reports. 2014;2014:bcr2013201637.","journal-title":"Case Reports"},{"key":"2336_CR21","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1111\/j.1523-1755.2004.00921.x","volume":"66","author":"ZH Bajwa","year":"2004","unstructured":"Bajwa ZH, Sial KA, Malik AB, Steinman TI. Pain patterns in patients with polycystic kidney disease. Kidney Int. 2004;66:1561\u20139.","journal-title":"Kidney Int"},{"key":"2336_CR22","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1590\/S0100-879X2006000400014","volume":"39","author":"EA Rom\u00e3o","year":"2006","unstructured":"Rom\u00e3o EA, Moys\u00e9s Neto M, Teixeira SR, Muglia VF, Vieira-Neto OM, Dantas M. Renal and extrarenal manifestations of autosomal dominant polycystic kidney disease. Brazilian J Med Biol Res. 2006;39:533\u20138.","journal-title":"Brazilian J Med Biol Res"},{"key":"2336_CR23","doi-asserted-by":"crossref","unstructured":"Alves M, Fonseca T, de Almeida EAF. Differential diagnosis of autosomal dominant polycystic kidney disease. Exon Publ. 2015;:3\u201319.","DOI":"10.15586\/codon.pkd.2015.ch1"},{"key":"2336_CR24","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1093\/ndt\/gfs417","volume":"28","author":"I Helal","year":"2013","unstructured":"Helal I, McFann K, Reed B, Yan X-D, Schrier RW, Fick-Brosnahan GM. Serum uric acid, kidney volume and progression in autosomal-dominant polycystic kidney disease. Nephrol Dial Transplant. 2013;28:380\u20135.","journal-title":"Nephrol Dial Transplant"},{"key":"2336_CR25","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/S0272-6386(00)70042-4","volume":"35","author":"I Ishikawa","year":"2000","unstructured":"Ishikawa I, Maeda K, Nakai S, Kawaguchi Y. Gender difference in the mean age at the induction of hemodialysis in patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis. 2000;35:1072\u20135.","journal-title":"Am J Kidney Dis"},{"key":"2336_CR26","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1053\/j.ajkd.2015.07.037","volume":"67","author":"FT Chebib","year":"2016","unstructured":"Chebib FT, Torres VE. Autosomal dominant polycystic kidney disease: core curriculum 2016. Am J Kidney Dis. 2016;67:792\u2013810.","journal-title":"Am J Kidney Dis"},{"key":"2336_CR27","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1093\/ndt\/16.2.410","volume":"16","author":"Y Shan","year":"2001","unstructured":"Shan Y, Lee P, Sy ED, Hung C, Lin Y. Polycystic kidney patient as a cadaveric donor: is it appropriate? Nephrol Dial Transplant. 2001;16:410\u20131.","journal-title":"Nephrol Dial Transplant"},{"key":"2336_CR28","doi-asserted-by":"crossref","unstructured":"Parmar S, Jain SK, Kaur G, Kumar A. Ontology Construction for Polycystic Kidney Disease. In: International Conference on Computing and Communication Systems. Springer; 2011. p.\u00a0245\u201354.","DOI":"10.1007\/978-3-642-29219-4_29"},{"key":"2336_CR29","doi-asserted-by":"publisher","first-page":"278","DOI":"10.5489\/cuaj.2128","volume":"8","author":"O Cristea","year":"2014","unstructured":"Cristea O, Yanko D, Felbel S, House A, Sener A, Luke PPW. Maximal kidney length predicts need for native nephrectomy in ADPKD patients undergoing renal transplantation. Can Urol Assoc J. 2014;8:278.","journal-title":"Can Urol Assoc J"},{"key":"2336_CR30","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1159\/000320745","volume":"117","author":"R Kazancioglu","year":"2011","unstructured":"Kazancioglu R, Ecder T, Altintepe L, Altiparmak MR, Tuglular S, Uyanik A, et al. Demographic and clinical characteristics of patients with autosomal dominant polycystic kidney disease: A multicenter experience. Nephron - Clin Pract. 2011;117:270\u20135.","journal-title":"Nephron - Clin Pract"},{"key":"2336_CR31","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12873-018-0192-3","volume":"18","author":"K Hajjar","year":"2018","unstructured":"Hajjar K, Chebl RB, Kanso M, Abou Dagher G. Autosomal dominant polycystic kidney disease and minimal trauma: medical review and case report. BMC Emerg Med. 2018;18:38.","journal-title":"BMC Emerg Med"},{"key":"2336_CR32","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1681\/ASN.V551178","volume":"5","author":"AB Chapman","year":"1994","unstructured":"Chapman AB, Johnson AM, Gabow PA, Schrier RW. Overt proteinuria and microalbuminuria in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 1994;5:1349\u201354.","journal-title":"J Am Soc Nephrol"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-021-02336-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-021-02336-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-021-02336-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,2]],"date-time":"2021-05-02T15:43:42Z","timestamp":1619970222000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-021-02336-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,28]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2336"],"URL":"https:\/\/doi.org\/10.1186\/s12882-021-02336-8","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,28]]},"assertion":[{"value":"3 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors give consent for the publication of text material including all identifiable details within this manuscript to be published in BMC Nephrology journal.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Committee of Heath Research Publications and Ethics of the Komfo Anokye Teaching Hospital. Data used was obtained in adherence to the principles of the declaration of Helsinki and local regulatory requirements.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Authors declare no competing interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"156"}}